Vif Hijacks CBF-β to Degrade APOBEC3G and Promote HIV-1 Infection
Stefanie Jäger,Dong Young Kim,Judd F. Hultquist,Keisuke Shindo,Rebecca S. LaRue,Eunju Kwon,Ming Li,Brett D. Anderson,Linda Yen,David Stanley,Cathal Mahon,Joshua Kane,Kathy Franks-Skiba,Peter Cimermancic,Alma Burlingame,Andrej Sali,Charles S. Craik,Reuben S. Harris,John D. Gross,Nevan J. Krogan
DOI: https://doi.org/10.1038/nature10693
IF: 64.8
2011-01-01
Nature
Abstract:Restriction factors, such as the retroviral complementary DNA deaminase APOBEC3G, are cellular proteins that dominantly block virus replication. The AIDS virus, human immunodeficiency virus type 1 (HIV-1), produces the accessory factor Vif, which counteracts the host's antiviral defence by hijacking a ubiquitin ligase complex, containing CUL5, ELOC, ELOB and a RING-box protein, and targeting APOBEC3G for degradation. Here we reveal, using an affinity tag/purification mass spectrometry approach, that Vif additionally recruits the transcription cofactor CBF-β to this ubiquitin ligase complex. CBF-β, which normally functions in concert with RUNX DNA binding proteins, allows the reconstitution of a recombinant six-protein assembly that elicits specific polyubiquitination activity with APOBEC3G, but not the related deaminase APOBEC3A. Using RNA knockdown and genetic complementation studies, we also demonstrate that CBF-β is required for Vif-mediated degradation of APOBEC3G and therefore for preserving HIV-1 infectivity. Finally, simian immunodeficiency virus (SIV) Vif also binds to and requires CBF-β to degrade rhesus macaque APOBEC3G, indicating functional conservation. Methods of disrupting the CBF-β-Vif interaction might enable HIV-1 restriction and provide a supplement to current antiviral therapies that primarily target viral proteins.